Clinical trialNCT00514501CompletedPhase 2Interventional

Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

SponsorMolecular Insight Pharmaceuticals, Inc.Enrollment510Acute Coronary Syndrome

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label phase 2 study recruiting low, moderate, and high likelihood ACS patients from approximately 60 centers. Patients will be imaged with iodofiltic acid I 123 for the detection of myocardial ischemia. Readers independent of the clinical study centers will review results of imaging studies in a blinded fashion at an imaging core lab. The resulting independent reading of the images will be compared against the truth standard for ACS.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Norman LaFrance, MD
Molecular Insight Pharmaceuticals, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Facility name not stated
North Vancouver, British Columbia, Canada
Facility name not stated
Scarborough Village, Ontario, Canada

United States

Facility name not stated
Birmingham, Alabama, United States
Facility name not stated
Huntsville, Alabama, United States
Facility name not stated
Mesa, Arizona, United States
Facility name not stated
Los Angeles, California, United States
Facility name not stated
Mission Viejo, California, United States
Facility name not stated
Newport Beach, California, United States
Facility name not stated
Roseville, California, United States
Facility name not stated
Hartford, Connecticut, United States
Facility name not stated
New Haven, Connecticut, United States
Facility name not stated
Newark, Delaware, United States
Facility name not stated
Jacksonville, Florida, United States
Facility name not stated
Aurora, Illinois, United States
Facility name not stated
Maywood, Illinois, United States
Facility name not stated
Louisville, Kentucky, United States
Facility name not stated
Auburn, Maine, United States
Facility name not stated
Bethesda, Maryland, United States
Facility name not stated
Detroit, Michigan, United States
Facility name not stated
Royal Oak, Michigan, United States
Facility name not stated
Troy, Michigan, United States
Facility name not stated
Minneapolis, Minnesota, United States
Facility name not stated
Kansas City, Missouri, United States
Facility name not stated
Lebanon, New Hampshire, United States
Facility name not stated
Manchester, New Hampshire, United States
Facility name not stated
Albany, New York, United States
Facility name not stated
Brooklyn, New York, United States
Facility name not stated
Kingston, New York, United States
Facility name not stated
New York, New York, United States
Facility name not stated
Rochester, New York, United States
Facility name not stated
Syracuse, New York, United States
Facility name not stated
Cincinnati, Ohio, United States
Facility name not stated
Cleveland, Ohio, United States
Facility name not stated
Columbus, Ohio, United States
Facility name not stated
Providence, Rhode Island, United States
Facility name not stated
Houston, Texas, United States
Facility name not stated
Richmond, Virginia, United States
Facility name not stated
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Iodofiltic acid I-123

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2007
Primary completion: 30 Jun 2008
Completion: 31 Dec 2008
Last update posted: 31 Mar 2016
Registered enrollment: 510
Registry id: NCT00514501

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.